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SEVERAL lines of research indirectly suggest that plate-
let  activating  factor  (PAF)  may  intervene  in  the
pathogenesis of extrinsic allergic alveolitis (EAA). The
specific aim of our study was to evaluate the participa-
tion  of  PAF  on  macrophage  activation  during  the
acute phase of EAA in an experimental model of this
disease developed in guinea pigs. Initially we meas-
ured  the  concentration  of  PAF  in  bronchoalvedar
lavage fluid, blood and lung tissue. In a second phase
we  evaluate  the  participation  of  PAF  on  alveolar
macrophage activation and parenchymal lung injury.
The  effect  of  PAF  on  parenchymal  lung  injury  was
evaluated by measuring several lung parenchymatous
lesion  indices  (lung  index,  bronchoalvedar  lavage
fluid  (BALF)  lactic  hydrogenase  activity  and  BALF
alkaline  phosphatase  activity)  and  parameters  of
systemic  response  to  the  challenge  (acute  phase
reagents). We observed that induction of the experi-
mental EAA gave rise to an increase in the concentra-
tion of PAF in blood and in lung tissue. The use of the
PAF-receptor  antagonist  BN52021  decreases  the
release  of  lysosomal enzymes (b -glucuronidase and
tartrate-sensitive  acid  phosphatase)  to  the  extrac-
ellular  environment  both in  vivo and  in  vitro.  Fur-
thermore, antagonism of the PAF receptors notably
decreases pulmonary parenchymatous lesion. These
data  suggest  that  lung  lesions  from  acute  EAA  are
partly mediated by local production of PAF.
Key words: platelet activating factor, alveolar macrophage,
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Introduction
Extrinsic allergic alveolitis (EAA) are a group of lung
diseases that result from repeated exposure to some
antigenic organic dusts.1 The disease mainly affects
the distal airways and is characterized by interstitial
and  alveolar  inflammation  often  associated  with
granulomas.2 EAA is a model of considerable interest
in  the  study  of  the  pathogenic  mechanisms  of
interstitial lung diseases since in this disease alveolitis
is more intense.3
Alveolitis  is  the  key  pathogenic  process  in  all
interstitial  diseases  and  is  characterized  by  two
fundamental features: an increase in the number of
alveolar  cells  and  the  activation  of  these  cells.
Although the type of inflammatory response varies in
different  species,  in  all  the  EAA  models  there  is  a
marked  increase  in  the  number  of  alveolar  macro-
phages (AM), thus implying that this cell type plays an
essential role in the pathogenesis.3,4 In EAA the AMs
are activated, and in response to the causal antigens
they release a large number of inflammatory media-
tors  (i.e.  lysosomal  enzymes,  oxygen  free  radicals,
cytokines, arachidonic acid metabolites) capable  of
injuring the lung parenchyma.5 Specifically, our group
has demonstrated the role of lysosomal enzymes both
in clinical6 and experimental7 EAA.
Diverse data suggest that platelet activating factor
(PAF) participates in the pathogenesis of  the acute
phase of EAA: (a) the pathological data observed in
patients with EAA and in animals subjected to models
of  this  disease  are  similar  to  those  obtained  after
intratracheal administration of PAF ,8 (b) AMs synthe-
size and release PAF in response to diverse stimuli9–11
and also have PAF receptors,12,13 and (c) one of the
effects of PAF on cells of the mononuclear phagocyte
system is the activation of these cells and the release
of different mediators (among which are lysosomal
enzymes).14,15
Hence, the specific aim of our study was to evaluate
the participation of PAF in two basic aspects of the
acute  phase  of  extrinsic  allergic  alveolitis:  macro-
phage activation and monocyte recruitment.
Material and Methods
Materials
Faenia rectivirgula (CECT 3223) was kindly provided
by the Departamento de Microbiologia (Facultad de
0962-9351/98/030201-10 $9.00 © 1998 Carfax Publishing Ltd 201
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strain  which  corresponds  to ATCC  15347.  F.  recti-
virgula was inoculated into trypticase-soy broth and
grown at 52°C for 6 days in a shaking incubator. It was
harvested by centrifugation at 450 3 g and washed
three  times  with  sterile  saline.  Cell  walls  were
disrupted with a Polytron homogenizer (Kinematica,
Kriens/Luzern,  Switzerland)  and  the  mixture  was
then sonicated (Sonifier, Branson Sonic Power Com-
pany,  Danford,  CT)  three  times  (20  periods). The
lysate was lyophilized and stored in sterile vials. BN
52021 was kindly provided by P. Braquet (IPSEN, 30
Rue Cambrone, Paris).
Animal model of extrinsic allergic alveolitis
Male  Dunkin-Hartley  guinea  pigs  (200–250g,  IFFA
Credo, Spain) were used for all studies. Principles of
Laboratory Animal Care, formulated by the National
Society for Medical Research were used as guidelines
for the  use  and care of animals. Guinea pigs were
housed in sterile rooms and were allowed food and
water  ad  libitum.  Intramuscular  injection  of  keta-
mine (100mg/ml body weight) for anaesthesia. EAA
was induced according to the protocol of Schuyler
and  Crooks16 with  minor  modifications7 (Fig.  1).
Lyophilized antigen was resuspended in pyrogen-free
saline at 4mg/ml and administered intratracheally at
3.6mg/kg  body  weight.  F.  rectivirgula antigen
(1.6mg) was emulsified in 400m l of complete Freund
adjuvant  (Sigma  F-5881)  for  intramuscular  inocula-
tion,  or  in  400m l  of  incomplete  Freund  adjuvant
(Sigma F-5506) for subcutaneous administration. Each
experimental  group  comprised  six  animals  and  a
control  group  of  six  normal  guinea  pigs  was  also
included in the study. All procedures were performed
using standard sterile materials. In a previous work
our group has demonstrated that saline intratracheal
inoculation did not modifies the parameters evaluated
when compared with control group.7
In vivo administration of BN 52021
The PAF receptor antagonist BN 52021 was diluted
daily  in  pyrogen  free  saline  and  inoculated  intra-
peritoneally  at  5mg/kg  body  weight.17 The  admin-
istration schedule is shown in Fig. 1.
Collection of samples
Two hours after the last intratracheal challenge with
Faenia  rectivirgula antigen,  the  guinea  pigs  were
sacrificed.  Bronchoalveolar  lavage  (BAL)  was  per-
formed  using  12ml  of  pyrogen-free  saline  in  three
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FIG. 1. Experimental protocol. CFA: Complete Freund adjuvant; IFA: Incomplete Freund adjuvantaliquots (3 3 4ml). A 2ml aliquot of bronchoalveolar
lavage  fluid  (BALF)  was  immediately  processed  for
PAF determination (see below). The rest of the fluid
was  filtered  through  sterile  gauze  and  then  cen-
trifuged at 500 3 g for 10min at 4°C. The supernatant
was immediately frozen at –70 °C and the cells were
resuspended in 2ml of phosphate-buffered saline.
Blood  was  obtained  by  direct  intracardiac  punc-
ture. A 1ml aliquot was used for PAF determination
(see below) and the rest was used to obtain serum,
which was then stored at –70°C.
The  lungs  were  then  dissected  and  weighed. A
small sample of the inferior right  lobe (by conven-
tion) was  excised, weighed and processed for  PAF
extraction.
Cytological studies of BAL
BAL cells were  counted on a  haemocytometer and
viability  was  assessed  by  Trypan  blue  exclusion.
Cytocentrifuge preparations were stained with Diff-
Quik® (American Scientific, McGaw Park, IL) and a
differential  count  was  performed,  200  cells  being
counted by two observers (T .M., M.L.S.). Non-specific
esterase and b -glucuronidase stains were performed
using commercially available reagents (Sigma Chem-
ical Company). Results for b -glucuronidase stain were
expressed both as the percentage of positive cells and
as intensity score according to Roodman (0: absence
of staining; 1: weak (less than 25%  cytoplasm stained);
2: moderate (25%  to 50% cytoplasm is tained) and 3:
intense (more than 50% stained).18
Studies of BALF
BAL fluid aliquots were used for the determination of
protein  concentration,  lactic  dehydrogenase  (LDH)
activity,  alkaline  phosphatase  activity  and  tartrate-
sensitive acid phosphatase activity. All measurements
were carried out on the same day and under the same
conditions to avoid interassay variability.
Total  protein  concentration  was  assayed  by  an
automated  cholorimetric  method19 using  reagents
provided by Boehringer  Mannheim.  Concentrations
were  expressed  in  micrograms  per  millilitre.  The
detection  limit  was  65m g/ml  and  the  intra-assay
coefficient of variation was 3.45% .
All enzymatic activities were measured at 37°C by
automated colorimetric methods20,21 using reagents
provided by Boehringer Mannheim and results were
reported  as  U/l. The  detection  limit  for  LDH  (EC
1.1.1.27) was 0.73 U/l and the intraassay coefficient
of variation was 2.4%. The detection limit for alkaline
phosphatase  (E.C.  3.1.3.1)  was  0.58  U/l  and  the
intraassay coefficient of variation was 2.26%. Tartrate-
sensitive acid phosphatase activity was calculated by
the  difference  between  total  and  tartrate-resistant
activity. The detection limit of total acid phosphatase
(EC  3.1.3.2)  and  tartrate-resistant  acid  phosphatase
were  respectively  0.01  U/l  and  0.025  U/l  with  an
intraassay coefficient of variation of 1.5%  and 7.27%.
Serum studies
Serum  aliquots were used for the determination of
total  protein  concentration,  serum  electrophoretic
protein  profile,  LDH  activity,  alkaline  phosphatase
activity and tartrate-sensitive acid phosphatase activ-
ity. All measurements were carried out on the same
day and under the same conditions to avoid interassay
variability.
Total  protein  concentration  was  analysed  by  an
automated colorimetric method22 using reagents pro-
vided by Boehringer Mannheim. Concentrations were
expressed in grams per decilitre. The detection limit
was  0.126g/dl  and  the  intraassay  coefficient  of
variation  was  1.21% .  Electrophoresis  on  cellulose
acetate was  used for separation  of  serum  proteins.
The  percentage  of  each  fraction  was  measured
automatically (Olympus Hyte-System 310) after stain-
ing  protein  bands  with  Ponceau  red. Results  were
reported as concentration of each fraction.
Serum enzyme activities were measured using the
same  techniques  as  for  the  bronchalveolar  lavage
fluid. The detection limit of serum LDH was 1.7 U/l
and the intraassay coefficient of variation was 0.53% .
For  serum  alkaline  phosphatase  the detection limit
was 1.38 U/l and the intraassay coefficient of variation
was  1.1% . The  detection  limit  of  total  serum  acid
phosphatase was 1.02 U/l and the intraassay coeffi-
cient of variation was 7.38%, and in the case of serum
tartrate-resistant acid phosphatase the detection limit
was 0.2 U/l and the intraassay coefficient of variation
3.13%.
Specific  antibodies  against  F.  rectivirgula were
detected  by  double  diffusion  in  agar23 using  a
commercial filtered antigen (Mercia Diagnostics Lim-
ited, UK). Positive and negative control sera were also
provided by Mercia Diagnostics.
PAF extraction and determination
Freshly  extracted BAL,  blood and  lung  tissue  were
immediately mixed with ice-cold acidified methanol
and PAF extracted was performed from the methanol
phase  by  a  modification  of  a  previously  described
method.24
BAL fluid (2ml) was mixed with 6ml of ice-cold
acidified  methanol  (Panreac)  containing  phenyl-
methyl-sulphonyl-fluoride  (PMSF  Sigma  Chemical
Company)  at  final  concentration  of  10–4 M.  After
vigorous  agitation,  8ml  of  chloroform  were  added
and  after  homogenization,  the  sample  was  cen-
trifuged  at  3500rpm  for  10min  (BHG-Hermle  Z
360K).  The  chloroform  phase  was  separated  and
fresh chloroform added to the methanol phase. The
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form  extracts  dried  under  nitrogen.  Samples  were
stored  at  –20°C  until  reconstitution  for  PAF
measurement.
A 1ml  sample of blood was  mixed with  5ml of
ice-cold acidified methanol immediately after cardiac
puncture. After  vigorous  agitation,  the  sample  was
slowly  stirred  for  30min  and  then  centrifuged  at
3500 rpm for 10min. The supernatant was retained
and  the  pellet  resuspended  in  5ml  of  ice-cold
acidified  methanol.  The  methanol  extracts  were
pooled  and  chloroform  and  water  were  added  to
give a methanol: chloroform: water ratio of 1:1:0.9,
and  gently  stirred.  After  phase  formation  by  cen-
trifugation, the chloroform phase was removed and
the methanol: water phase extracted with a further
similar  volume  of  chloroform.  The  chloroform
extracts  were pooled and dried under nitrogen.
Lung tissue was mixed with 5ml of cold acidified
methanol,  subjected  to  mechanical  disruption  at
9000g  for  30s  (Polytron  PT  10–35  Kinematica AG
Kriens-Luzern  Switzerland)  and  then  slowly  stirred
for  30min.  The  tubes  were  centrifuged  and  the
pellet was again mixed with 5ml of acidified metha-
nol. The  methanol  extracts  were  pooled  and  PAF
extracted and processed as for blood.
PAF  extraction from  chloroform  phases  was  per-
formed with Bond-Elut C-18 cartridges (Varian, Cam-
bridge, UK). The cartridges were rinsed sequentially
with  2ml  of  methanol,  2ml  of  distilled  water  and
2ml of acetic acid 10% . Samples were resuspended
in  2ml  of  acidified chloroform  and applied to  the
cartridge.  Columns  were  eluted  sequentially  with
two 1ml aliquots of acetic acid, three 2ml aliquots
of  ethyl  acetate  and one  6ml  aliquot  of  methanol.
The last  fraction  containing PAF was collected and
dried  under  nitrogen. With  this  method  the  mean
recovery obtained, using 3H-PAF as tracer, was 57 ±
3.5%.
PAF determination was performed by radioimmu-
noassay (New  England  Nuclear  Division, Dreiteich,
Germany)  following  the  instructions enclosed with
the product. Briefly, dried samples were resuspended
in 2ml of working assay buffer (0.1 sodium acetate
and 0.05% Tween 20 in 50mM sodium citrate buffer,
pH  6.3).  Primary  antibody  solution  (100m l)  was
added to  100m l  of  each  sample  and incubated for
15min at room temperature. Then 100m l of second-
ary  antibody/tracer  solution  (125I-PAF ,  0,15m Ci/ml)
were added to each tube and incubated 15–24h at
room  temperature.  Bound  and  free  antigen  were
separated  by  centrifugation  (1000–2000  3 g for
30min)  and decantation  after  adding 2ml  of  assay
buffer to each tube. A standard curve was made using
concentrations of 0.3–30ng/ml. Nonspecific binding
(3% ) was determined in four tubes without antibody
solution and total binding was calculated in four tubes
without unlabelled antigen.
Anti-PAF  antibodies  were  assayed  for  cross-reac-
tivity against several compounds with the following
results: arachidonic acid 0.002% ; phosphatidylcholine
0.06%; phosphatidylethanolamine 0.03% and lysoPAF
0.003% .
After PAF extraction, several concentrations of PAF
were  added  to  five  aliquots  from  a  sample  and
measurements  by  radioimmunoassay  were  used  to
calculate the recovery and accuracy of the method.
The  mean  recovery  observed  was  88  ±  5%.  The
intraassay variation coefficient was 8.5% ± 0.5%  (n =
5) and the intraassay variation coefficient was 9.3%  ±
0.7% (n = 4).
Lung index
The  lungs,  with  trachea  intact,  were  isolated  and
weighed  to  determine  lung  index,  defined  as
follows.25
Lung index =
Lung weight/Body weight test animal
Lung weight/Body weight normal animal
In vitro secretion of acid phosphatase by
guinea-pig AMs
AMs were recovered from normal guinea pigs by BAL
which  was  performed  using  20ml  of  pyrogen-free
saline in five aliquots (4 3 5ml). The BAL fluid was
first filtered through sterile gauze and centrifuged on
a Ficoll-Hypaque gradient (450 3 g, 30min at 20°C).
After separation and two washings with sterile PBS,
cells were resuspended in RPMI 1640 supplemented
with 10%  FCS (fetal calf serum), 2mM glutamine and
penicillin-streptomicin (complete medium).
Cells were plated in four culture plates (Costar) in
1ml of complete medium and allowed to adhere for
2h  at  37°C,  5%  CO2.  Non-adherent  cells  were
removed and 1ml of fresh medium was added. Cells
were  incubated  alone  or  with  300m M  BN52021,
opsonized zymosan (400m g/ml) and both BN 52021
and opsonized zymosan (BN52021 was added 15min
before the zymosan). After 24h at 37°C, 5%  CO2, the
supernatant  was  collected  and  400m l  of  sucrose-
EDTA buffer added to the cell monolayer. The cells
were lysed by six freeze–thawing cycles. Acid phos-
phatase and LDH were measured in the supernatant
and in the cell lysate.
Statistical analysis
Statistical analysis was performed using the unpaired
t-test, simple linear regression and one or two tailed
ANOVA using  the StatworksTM and StatviewTM soft-
ware program  for the Apple MacintoshTM. Data  are
expressed as means ± SD. For comparisons, P values <
0.05 are considered as significant.
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Mean SD Mean SD Mean SD Mean SD
Total cell counts 0.49 0.26 0.89 0.44 1.96a,b 1.18 1.77a,b 0.80
(3 106/ml BALF)
BALF MPS cells 49.2 32.0 77.2 37.8 97.3a 37.3 96.0a 39.3
(3 104/ml BALF)
BALF lymphocytes 0.1 0.3 0.2 0.4 2.16a,b 1.1 0.2c 0.4
(3 104/ml BALF)
BALF neutrophils 0.2 0.4 0.1 0.2 0.4 1.2 0.1 0.2
(3 104/ml BALF)
BALF eosinophils 28.6 28.3 11.6 5.1 109.1a,b 95.4 81.8a,b 49.5
(3 104/ml BALF)
Lung index 0.9 0.12 1.01 0.08 1.70a,b 0.30 1.40c 0.20
BALF total protein 80 15.5 91 28.5 191a,b 133 162 89
(m g/ml)
EAA: Extrinsic allergic alveolitis; BALF: bronchoalveolar lavage fluid; MPS: mononuclear phagocyte system.
a P < 0.05 compared with control group;
b P < 0.05 compared with control + BN 52021 group;
c P < 0.05 compared with EAA group.
FIG. 2. PAF concentrations in the experimental groups. Data
are mean ± SD of triplicate measurements from three guinea
pigs/group  and  were  analysed  by  two-way  analysis  of
variance and multiple mean comparison test. Asterisks (w )
represent significant differences (P < 0.05) with respect to
control group and stars (q ) significant differences (P < 0.05)
with respect to the acute EAA group.
Results
Validation of the animal model
In order to verify that the animals subjected to the
experimental protocol had developed a disease char-
acteristic  of  extrinsic  allergic  alveolitis,  different
parameters were evaluated. Initially we observed that
precipiting  antibodies  to  Faenia  rectiv´ õrgula
appeared in the serum of all the guinea-pigs inocu-
lated intratracheally with particulate antigen. Moreo-
ver, in this experimental group there was an intense
alveolitis  (mainly  mononuclear  phagocyte  system
cells and eosinophils), and a rise in the lung index and
in protein concentration in the BALF (Table 1).
PAF measurements
The guinea pigs in the group subjected to the EAA
experimental model showed a significant rise in PAF
concentration in blood and lung tissue with respect to
the control group (Fig. 2). However, there were no
significant differences in the PAF values in the BALF ,
either when the results were expressed by volume
unit  or  as  total  PAF  recovered. Treatment  with  BN
52021  prior  to  the  induction  of  EAA  reduces  PAF
levels in the blood, but increases PAF concentration in
the lung tissue.
In vivo effect of PAF-receptor antagonist on
macrophage activation
The  participation  of  PAF  in  macrophage  activation
was examined using two complementary methods. In
vivo AM  activation  was  examined  by  measuring
lysosomal enzyme activities (in both intra and extrac-
ellular  compartments)  in  the  animal  model  in  the
presence or absence of an inhibitor of PAF receptors
(BN 52021). In the guinea pigs subjected to the EAA
experimental  model  there  was  a  decrease  in intra-
macrophage lysosomal enzymes activity (Fig. 3) and
an increase in extracellular activity in both BALF and
serum (Fig. 4). Treatment with BN 52021 prior to EAA
induction significantly reduced the release of lysoso-mal  enzymes  as  the  percentage  and  the  score  of
b -glucuronidase were higher than in the acute EAA
group. Moreover, there was less tartrate-sensitive acid
phosphatase  activity  in  BALF  and  in  serum  if  the
animals were pretreated with BN 52021 before being
subjected to the EAA model.
In vitro effect of PAF-receptor antagonist on
macrophage activation
We also studied the effect of BN 52021 in vivo on the
release of lysosomal enzymes in the alveolar macro-
phages  of  control  guinea  pigs  stimulated  by  a
particulate antigen. The results (Fig. 5) indicate that
preincubation with BN 52021 inhibited significantly
the release of lysosomal enzymes both after stimula-
tion with the particulate antigen and in basal condi-
tions.  Simultaneous  measurement  of  LDH  in  the
supernatant  and in the cell  lysate  showed that  the
release of lysosomal enzymes to the culture was an
active process since 25–45% acid phosphatase was
released as against 10–13%  of LDH.
Effect of PAF-receptor antagonism on
parenchymal lung injury
The effect of PAF on parenchymal  lung  injury was
evaluated  by  measuring  the  effect  of  BN52021  on
lung  parenchymatous  lesion  indices  (lung  index,
BALF  LDH  activity  and  BALF  alkaline  phosphatase
activity) and parameters of systemic reponse to the
challenge (acute phase reagents).
In our study we observed that treatment with BN
52021 prior to EAA induction significantly reduced
the lung index (Table 1). Although the lung index is
non-specific,  since  many  factors  intervene  in  lung
weight,  the  notable  decrease  induced  by  the  PAF
antagonist clearly indicates a reduction of the inflam-
matory component in the lung parenchyma.
The total  protein concentration in the  BALF is a
useful  index  in  the  evaluation  of  lung  lesion  in
interstitial diseases. In our study, the use of BN 52021
in EAA affected this parameter in a similar way to the
lung index (Table 1).
In  this  study  maximum  values  of  BALF  LDH
activity were detected in the acute EAA group and
treatment  with  BN  52021  prior  to  EAA  induction
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FIG. 3. In vivo effect of BN52021 on intracellular lysosomal
enzymes. Data are mean ± SD of six guinea pigs/group and
were analysed by one-way analysis of variance and multiple
mean  comparison  test. Asterisks (w ) represent significant
differences (P< 0.05) with respect to control group and stars
(q ) significant differences (P< 0.05) with respect to the acute
EAA group.
FIG. 4. In vivo effect of BN52021 on extracellular lysosomal
enzymes. Data are mean ± SD of six guinea pigs/group and
were analysed by one-way analysis of variance and multiple
mean  comparison  test. Asterisks (w ) represent significant
differences (P< 0.05) with respect to control group and stars
(q ) significant differences (P< 0.05) with respect to the acute
EAA group.
FIG. 5. Effect of BN52021 in vitro on alveolar macrophage
lysosomal enzyme release. Each column shows mean ± SEM
of values obtained in three separate experiments. Results are
expressed  as  percentage  of  the  control  group  value
(=100% ).Role of PAF in EAA
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Mean SD Mean SD Mean SD Mean SD
BALF LDH activity 0.89 0.42 1.07 0.36 97.17a,b 36.8 1.93c 0.90
(U/l)
Serum LDH activity 619 110 426 96 557 277 522 150
(U/l)
BALF alkaline 5.1 2.0 11.2 3.0 33.6a,b 17.0 37.9a,b 11.0
phosphatase (U/l)
Serum alkaline 629 113 647 38 331a,b 1.2 461c 118
phosphatase (U/l)
a P < 0.05 compared with control group;
b P < 0.05 compared with control + BN 52021 group;
c P < 0.05 compared with EAA group.












Mean SD Mean SD Mean SD Mean SD
Albumin (g/dl) 3.12 0.35 2.96 0.05 2.71a,b 0.17 2.50a,b 0.40
a -globulin (g/dl) 1.06 0.10 1.03 0.05 1.26a,b 0.17 1.14c 0.07
b -globulin (g/dl) 0.24 0.04 0.31 0.04 0.38a,b 0.05 0.41a,b 0.04
g -globulin (g/dl) 0.17 0.03 0.17 0.04 0.37a,b 0.10 0.38a,b 0.08
EAA: Extrinsic allergic alveolitis; BALF: bronchoalveolar lavage fluid.
a P < 0.05 compared with control group;
b P < 0.05 compared with control + BN 52021 group;
c P < 0.05 compared with EAA group.
FIG. 6. Relationship between BALF LDH activity and lysosomal enzymes in acute EAA groups. Data were analysed by Pearson’s
correlation test.reduced BALF LDH activity to values similar to those
of  the  controls  (Table  2). The  plasmatic  values  of
LDH are similar in all the experimental groups (Table
2). On the other hand, there was a negative correla-
tion between LDH catalytic activity in the BALF and
intracellular lysosomal activity, and a positive correla-
tion with tartrate-sensitive acid phosphatase activity
in the BALF (Fig. 6).
Our results show a marked rise in alkaline phospha-
tase activity in acute EAA with respect to both control
groups (Table 2). However, in contrast to the results
obtained  with  the  other  lung  lesion  indices,  prior
administration  of  BN  52021  did  not  modify  the
activity of this enzyme in the BAL.
Guinea  pigs  with  experimental  EAA  showed,  as
expected, an increase in the plasma electrophoretic
fractions corresponding to acute phase reagents, as
well as hypergammaglobulinaemia and the presence
of  serum  precipitins (Table 3). The use of  the PAF
antagonist did not modify either the intensity of the
immunoglobulin response or the presence of precip-
itins. However, guinea pigs treated with BN 52021
prior to EAA induction showed lower concentrations
of the a globulin fraction than the acute EAA group.
Discussion
The pathogenic role of PAF in EAA was examined in a
guinea-pig  model.  We  first  verified,  using  various
parameters, the validity of the model. Although there
are  no  criteria  unanimously  established  in  the  lit-
erature, since our experimental model combines the
isolated criteria used separately by other authors, we
are confident that it is adequate.26–31
Subsequently,  we  measured the  concentration  of
PAF in BALF , blood and lung tissue in order to evaluate
the overall participation of PAF in the acute phase of
EAA.  Our  results  showed  a  significant  rise  in  PAF
concentration in blood and lung tissue with respect to
the control group, but  no significant differences in
the PAF values in the BALF . These data are similar to
those  obtained  by  Chang  et  al.32 after  peritoneal
administration of endotoxin in rats. The discrepancy
between  the results obtained in lung  tissue and in
BALF can be explained by compartmentalization of
the  inflammatory  response  in the lung  interstitium
and/or by in situ degradation of the PAF mediated by
acetylhydrolase  in  the  alveolar  region.  In  fact,  an
increase in number  of macrophages in the lung  of
animals with EAA might be expected to cause local
increases  in  PAF  acetylhydrolase  activity.33 Another
suggestive explanation of the absence of PAF in the
BALF is its retention by alveolar cells because of the
high affinity of this lipid mediator for the membranes.
Treatment with BN 52021 prior to the induction of
EAA reduces PAF levels in the blood, but increases
PAF concentration in the  lung  tissue. One possible
explanation for this finding is the different regulation
of PAF synthesis in diverse body compartments. Thus,
although  in  some  tissues  PAF  may  have  a  positive
autocrine  stimulation  of  PAF  synthesis, in the lung
blockade  of  PAF  receptors  could  increase  free-PAF .
However, PAF concentration in blood, which can be
interpreted as the net result of the production by the
different tissues, decreases on administering the PAF-
receptor antagonist.
The preadministration of PAF-receptor antagonism
reduces in vivo lysosomal enzymatic release (meas-
ured by biochemical and cytochemical methods) but
does  not  abolish  enzyme  release  in  response  to
particulate antigens. In order to  confirm  this inter-
pretation, AMs from healthy guinea pigs were culti-
vated in the presence of a particulate antigen, since
under these conditions, enzymes are released to the
extracellular environment.15 The results indicate that
preincubation  with  BN  52021  inhibited  the  active
release of lysosomal enzymes both after stimulation
with the particulate antigen and in basal conditions. It
should be noted that there was a difference between
the effect of BN 52021 in vivo, where there was no
change in lysosomal enzymatic release, and the results
obtained  in  vitro.  This  may  be  an  experimental
artifact,  as  manipulation  of  the  cells,  and  even
adherence  to  the  plastic,  can  cause  PAF  release.
Hence,  it  can  be  concluded  that  inhibition  of  PAF
receptors reduces lysosomal enzyme release both in
vivo and in vitro. These results are similar to those
obtained in monocytes by Shen et al.14 who demon-
strated that release of lysosomal enzymes was inhib-
ited  by  kadsurenone,  another  PAF-receptor
antagonist.
Diverse parameters have been used in the literature
to evaluate, and to some extent quantify, parenchymal
lung injury. Those most commonly used in lung lesion
experimental  models  are  the  lung  index,  protein
concentration  in  BALF ,  LDH  activity  and  alkaline
phosphatase  activity.  The  lung  index  is  an  easily
obtained parameter which indicates the existence of a
pulmonary  inflammatory  phenomenon. This  index
was first described by Wilson et al.25 and validated by
other  authors.31 In  our  study  we  observed  that
treatment  with  BN  52021  prior  to  EAA  induction
significantly  reduced  the  lung  index. Although  the
lung index is non-specific, since many factors inter-
vene in lung weight, the notable decrease induced by
the PAF antagonist clearly indicates a reduction of the
inflammatory  component  in  the  lung  parenchyma.
Similar results were obtained when we evaluated the
total protein concentration in the BALF .
BALF LDH activity measurement has been used as a
lung lesion index in diverse experimental models34,35
and in human diseases.36,37 Since this is a cytoplasmic
enzyme, its presence in a biological fluid indicates
cytolysis. Although it is not very likely, owing to the
pulmonary location of the inflammation, this enzyme
could  also  come  from  the  plasma  and  cross  the
J-L. P´ erez-Arellano et al.
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bility which takes place in acute EAA. However, in our
study we can reasonably reject this origin since the
plasmatic  values  of  LDH  are  similar  in  all  the
experimental groups. Hence, we can conclude that
inhibition  of  the  effects  of  PAF  on  the  lung
parenchyma  gives  rise  to  a  decrease  in  local  cell
destruction. If one takes into account  the fact that
activated macrophages are more sensitive to destruc-
tion after phagocytosis38 and the stabilizing effect of
BN52021  on  macrophage  lysosomes,  then  the
decreased  BALF  LDH  levels  may  be  due  to  the
decrease in macrophage activation. In support of this
proposal  we  found  a  negative  correlation  between
LDH  catalytic  activity  in the  BALF  and intracellular
lysosomal  activity,  and  a  positive  correlation  with
tartrate-sensitive  acid  phosphatase  activity  in  the
BALF .
Alkaline phosphatase activity in the lower respira-
tory  tract  is  limited  to  type  II  pneumocytes.39
Measurement of this enzyme activity in the BALF has
been used as an index of lesion and/or proliferation of
these  cells.40,41 Since  in  acute  EAA  there  is  an
hypertrophy  of  type  II  pneumocytes  as  well  as
notable structural alterations in these cells,42 we used
this measurement to evaluate their involvement. Our
results show a marked rise in alkaline phosphatase
activity in acute  EAA with  respect  to both control
groups. However, in contrast to the results obtained
with the other lung lesion indices, prior administra-
tion of BN 52021 did not modify the activity of this
enzyme  in  the  BAL.  One  possible  reason  for  this
discrepancy  is  the  great  avidity  of  the  type  II
pneumocytes for PAF , 95%  of the radiolabelled PAF
instilled into the  rat  lung  airways  being  selectively
retained  by  these  cells.43 Since  this  effect  is  not
antagonized by BN 52021 and the high lipid content
of these cells, it is possible that PAF-type II pneumo-
cyte interaction is not mediated by receptors.
In summary, the data from this paper suggest that
lung lesions from acute EAA are partly mediated by
local production of PAF through  modulation of AM
activation.
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